Peer-reviewed veterinary case report
L-659,066 reduces slow heart rate but not sedation
By Honkavaara, Juhana M et al.·Published in Veterinary anaesthesia and analgesia·2008·Department of Equine and Small Animal Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The effects of L-659,066, a peripheral alpha2-adrenoceptor antagonist, on dexmedetomidine-induced sedation and bradycardia in dogs.
- Species:
- dog
Plain-English summary
A group of healthy Beagle dogs was given a sedative called dexmedetomidine, which usually slows down the heart rate. Researchers tested whether adding another drug, L-659,066, would help keep the heart rate higher while still providing sedation. They found that the combination did not change how sedated the dogs felt but did help maintain a higher heart rate during sedation. After the sedation wore off, the dogs recovered without any issues. This suggests that L-659,066 could be a helpful addition to reduce heart-related side effects from dexmedetomidine in dogs.
People also search for: dog sedation heart rate · dexmedetomidine effects on dogs · Beagle sedation recovery
Abstract
OBJECTIVE: To investigate the influence of L-659,066, a peripheral alpha2-adrenoceptor antagonist, on dexmedetomidine-induced sedation and reduction in pulse rate (PR) in dogs. STUDY DESIGN: Randomized, cross-over. Animals Six healthy laboratory Beagles. METHODS: All animals received dexmedetomidine (5 microg kg(-1) IV, DEX) alone or in combination with L-659,066 (250 microg kg(-1) IV, DEX + L) with a 7-day rest period between treatments. Sedation was assessed using a composite sedation score and PRs were recorded. Atipamezole (50 microg kg(-1) IM, ATI) was administered to reverse the sedation. Overnight Holter-monitoring was carried out to obtain a minimum heart rate (MHR) at rest. RESULTS: Bioequivalence was shown for clinical sedation between DEX and DEX + L. Heart rate was significantly higher with DEX + L during the period of sedation. Bioequivalence was demonstrated between MHR and PR in the DEX + L group during the period of sedation. Recoveries after ATI were uneventful. CONCLUSIONS: L-659,066 did not affect the quality of dexmedetomidine-induced sedation whilst it attenuated the reduction in PR. Thus, L-659,066 could prove a useful adjunct to reduce the peripheral cardiovascular effects attributed to dexmedetomidine in dogs. CLINICAL RELEVANCE: The clinical safety of alpha2-adrenoceptor agonists could be markedly improved with less peripheral cardiovascular effects.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18466161/